BFC Planning, Inc.’s Madrigal Pharmaceuticals MDGL Stock Holding History

BFC Planning, Inc.’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2K	Hold	19	–	–	﹤0.01%	2363
2026 Q1	$9.9K	Sell	19 -4	-17%	-$1.91K	﹤0.01%	2055
2025 Q4	$13.4K	Hold	23	–	–	﹤0.01%	1939
2025 Q3	$10.5K	Hold	23	–	–	﹤0.01%	1893
2025 Q2	$6.96K	Hold	23	–	–	﹤0.01%	1945
2025 Q1	$7.62K	Buy	23 +4	+21%	+$1.31K	﹤0.01%	1875
2024 Q4	$5.86K	Buy	+19	New	+$5.34K	﹤0.01%	1963

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFC Planning, Inc.'s MDGL Position: Q2 2026 in Review

BFC Planning, Inc. held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 19 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

BFC Planning, Inc. first reported a position in MDGL in Q4 2024 and has held it in 7 quarters since. The position peaked at $13.4K in Q4 2025. 416 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

BFC Planning, Inc. held 19 shares of Madrigal Pharmaceuticals worth $10.2K as of Q2 2026.
BFC Planning, Inc. left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #2363 holding.
BFC Planning, Inc. first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
BFC Planning, Inc.'s Madrigal Pharmaceuticals position peaked at $13.4K in Q4 2025.
416 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.